Published

Psychedelic microdosing benefits and challenges: an empirical codebook.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Harm reduction journal
Date: 2019-07-10
Source: PubMed
DOI: 10.1186/s12954-019-0308-4
PubMed: 31288862

Authors

Anderson T Petranker R Christopher A Rosenbaum D Weissman C Dinh-Williams LA Hui K Hapke E

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Mechanism of Action Aging Microdosing Healthcare Workers Adverse Events Qualitative Study

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 Evaluating psilocybin for the management of depression: a literature review2026-08-02 Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)2026-03-26 Psychedelic microdosing benefits and challenges: an empirical codebook.2019-07-10

Related papers

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-21